NervGen is restoring life's potential by creating innovative solutions for the treatment of nerve damage.

NervGen is advancing its lead compound, NVG-291, for the treatment of spinal cord injury and multiple sclerosis, two indications that have significant market opportunities, are a high cost burden to the healthcare system and have a dramatic impact on quality of life. As a therapy, NVG-291 has shown remarkable preclinical promise to alleviate or improve the symptoms and conditions associated with spinal cord injury and multiple sclerosis, potentially allowing human patients to live more active and productive lives. There are currently no therapeutics approved for either nerve regeneration or remyelination.

In addition to spinal cord injury and multiple sclerosis, the Company is embarking on a research initiative to advance its proprietary therapeutic technology platform to generate new treatments for Alzheimer's disease, a progressive neurodegenerative disorder that destroys memory and cognitive functions. Alzheimer's disease is becoming a healthcare crisis with an estimated 30 million people affected globally, including 5.8 million in the United States. As Alzheimer's disease research and development efforts have had limited success in producing new effective treatments, the medical community and pharmaceutical industry are seeking technologies with novel approaches through new targets and pathways.

The Company plans to initiate a Phase 1a human clinical trial on healthy subjects in 2020 and an expansion to a Phase 1b in spinal cord injury patients. In addition, NervGen intends to commence a Phase 2a multiple sclerosis or remyelination clinical trial in 2021.

NervGen’s platform technology targets protein tyrosine phosphatase sigma ("PTPσ"), a neural receptor that impedes nerve regeneration and remyelination. Inhibition of the PTPσ receptor has been shown to promote regeneration of damaged nerves and improvement of nerve function in animal models for various medical conditions. NervGen’s core technology has also been shown to remyelinate nerves in demyelinated regions, leading to functional improvement.

Our Team

Protein Tyrosine Phosphatase sigma (PTPσ)


PTPσ inhibitors could revolutionize the treatment of spinal cord injury and conditions related to nerve damage by being the first therapeutic to

  • overcome the body's inhibitory mechanism to nerve growth, 

  • promote nerve regeneration, and

  • bring functional benefit to patients with nerve damage.

Latest News and Publications
NervGen Receives Investment from Drug Manufacturing Partner


NervGen Pharma Expands Platform into Alzheimer's Disease/NervGen Pharma's NVG-291 Compound on Track to Begin Phase 1 in Q1 2020


NervGen Announces Clinical Development Plan for the Treatment of Nerve Damage and Neurodegenerative Diseases and Results of Annual General Meeting of Shareholders


Corporate Presentations


NervGen Corporate Presentation


NervGen Corporate Presentation - Slide 9 video "Dramatic Improvement Observed"


NervGen Corporate Presentation - Slide 13 video "MS Mouse Model Video"

© 2019



Website last updated November 18, 2019. The information posted was accurate at the time of posting, but may be superseded by subsequent disclosures.  

This website may include predictions, estimates or other information that might be considered forward-looking. While these forward-looking statements represent our current judgment on what the future holds, they are subject to risks and uncertainties that could cause actual results to differ materially. You are cautioned not to place undue reliance on these forward-looking statements. Please keep in mind that we are not obligating ourselves to revise or publicly release the results of any revision to these forward looking statements in light of new information or future events. You should also review our most recent filings on SEDAR ( for a more complete discussion of these factors and other risks, particularly under the heading “Risk Factors.”